The Kingdom of Bahrain’s National Health Regulatory Authority (NHRA) today approved the emergency use of the COVID-19 vaccination, COVAXIN, produced by the Indian multinational biotechnology company, “Bharat Biotech”.
The decision follows the careful evaluation of data provided by the manufacturer, Bharath Biotech India, carried out by the NHRA’s Clinical Trials Committee and the Ministry of Health’s Immunization Committee.
More than 26,000 people participated in the vaccine’s clinical trials, which established that the two-dose regimen vaccine is 77.8% effective against COVID-19, and 93.4% effective against severe cases of COVID-19. Safety data indicated a low incidence of adverse effects.
